Novo-backed immuno-oncology drug developer Checkmate Pharmaceuticals has filed to go public a month after its last funding round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.

UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Nikon and Varian-backed cell biology technology developer floated in a $178m offering and its shares almost tripled in price on their first day of trading.

GlaxoSmithKline is paying $176m for a 10% stake in the RNA drug developer in connection with a strategic partnership agreement.

The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.

Alphabet and EmblemHealth returned to help supply $53.5m for the community-focused care provider, bringing its overall funding to nearly $140m.

Adimab's coronavirus antibody spinoff has launched with series A financing from investors including GV as it prepares for its first clinical trials.

Chinese Academy of Sciences' Cash Holdings invested with its affiliate fund Guoke Ruihua to aid Shanghai Topgen's biotech development.